X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PH15 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action. It is being evaluated for the treatment to improve psychomotor or cognitive impairment caused by mental fatigue.
Lead Product(s): PH15
Therapeutic Area: Psychiatry/Psychology Product Name: PH15
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
PH94B (fasedienol) is a first-in-class, rapid-onset investigational pherine nasal spray. It is being evaluated for the acute treatment of social anxiety disorder.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Product Name: PH94B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
Vistagen intends to use the proceeds for research and development associated with development of its product candidates, including its Phase 3 program for fasedienol, an investigational neuroactive pherine nasal spray, for anxiety in adults with social anxiety disorder.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Product Name: PH94B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2023
Details:
PH80 is a first-in-class, rapid-onset product candidate, designed to be used in a manner analogous to a rescue inhaler for acute management of the symptoms of premenstrual dysphoric disorder.
Lead Product(s): PH80
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: PH80
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pherin Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Product Name: PH94B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
PH10 (itruvone) is an investigational pherine nasal spray designed to engage and activate chemosensory neurons in the nasal passages connected to neural circuits in the brain that produce antidepressant effects.
Lead Product(s): Itruvone
Therapeutic Area: Psychiatry/Psychology Product Name: PH10
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
PH10 (itruvone) is an investigational pherine nasal spray designed to engage and activate chemosensory neurons in the nasal passages connected to neural circuits in the brain that produce antidepressant effects for Major Depressive Disorder patients.
Lead Product(s): Itruvone
Therapeutic Area: Psychiatry/Psychology Product Name: PH10
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
PH80 is a first-in-class, rapid-onset product candidate, designed to be used in a manner analogous to a rescue inhaler for acute treatment of hot flashes (vasomotor symptoms) in women diagnosed with menopausal hot flashes.
Lead Product(s): Epoxyestrenolone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: PH80
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
AV-101 (4-chlorokynurenine) is an oral prodrug, which is a potent and selective full antagonist of the glycine co-agonist site of the NMDAR that inhibits certain functions of the NMDAR. It has the potential to treat multiple CNS disorders.
Lead Product(s): 4-Chlorokynurenine
Therapeutic Area: Neurology Product Name: AV-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Product Name: PH94B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
